• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BIOLASE Showcases Advanced YSGG Laser Solutions for Periodontal and Implant Care at GNYDM 2025

    11/25/25 9:00:00 AM ET
    $BIOL
    Medical/Dental Instruments
    Health Care
    Get the next $BIOL alert in real time by email

    NEW YORK, Nov. 25, 2025 /PRNewswire/ -- BIOLASE, the global leader in dental lasers, announced its participation in the 2025 Greater New York Dental Meeting (GNYDM), taking place November 28–December 3 in New York City. As part of the program, BIOLASE will host a featured lecture led by Philip Kang, DDS, focused on advancing laser solutions for periodontal and implant health.

    BIOLASE Logo (PRNewsfoto/BIOLASE MG LLC)

    BIOLASE to Highlight YSGG Laser Innovations at GNYDM 2025

    Dr. Kang will present "Advancing Laser Solutions for Periodontal and Implant Health" on Sunday, November 30 from 10:00 AM to 12:30 PM on the GNYDM Main Stage (3 CE credits). The session will explore how Er,Cr:YSGG laser technology elevates clinical outcomes, enhances patient experience, and drives practice growth.

    The presentation will cover key learning objectives:

    • Understand the principles of Er,Cr:YSGG laser technology and its mechanism of action
    • Identify the clinical advantages of using YSGG lasers in periodontal and implant procedures
    • Recognize how YSGG lasers can improve patient comfort, efficiency, and outcomes
    • Evaluate how laser technology can support practice expansion and new service offerings

    "Laser dentistry continues to redefine modern periodontal and implant care," said Dr. Kwang Bum Park, CEO of BIOLASE. "We are pleased to share how our YSGG technology is shaping more predictable, comfortable, and minimally invasive treatment pathways for clinicians and their patients."

    Visit BIOLASE Booth #4129 for Exclusive GNYDM Show Pricing

    Throughout the meeting, attendees are invited to visit BIOLASE Booth #4129 to experience hands-on demos of the Waterlase iPlus® and explore an exclusive show-only pricing package available to GNYDM attendees. The booth will feature live laser demonstrations, clinical discussions, and opportunities to speak with BIOLASE educators and specialists about integrating all-tissue laser technology into their practice.

    BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE MG LLC.

    For updates and information on BIOLASE and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Instagram at www.instagram.com/biolase_official, and LinkedIn at www.linkedin.com/company/biolase/.

    About BIOLASE

    BIOLASE is the world's leading innovator in dental laser technology, manufacturing high-performance laser systems that advance dentistry and improve patient experiences. With a legacy of over three decades, BIOLASE continues to define the future of minimally invasive dentistry.

    Media Contact

    Denise Arterberry

    Marketing Manager, BIOLASE

    [email protected]

    949.226.8190

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biolase-showcases-advanced-ysgg-laser-solutions-for-periodontal-and-implant-care-at-gnydm-2025-302625037.html

    SOURCE BIOLASE

    Get the next $BIOL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIOL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIOL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Yale Kenneth P.

    4 - BIOLASE, INC (0000811240) (Issuer)

    6/12/23 9:10:00 AM ET
    $BIOL
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Somerman Martha J. Dds, Phd

    4 - BIOLASE, INC (0000811240) (Issuer)

    6/12/23 9:08:49 AM ET
    $BIOL
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Roper Jess

    4 - BIOLASE, INC (0000811240) (Issuer)

    6/12/23 9:07:19 AM ET
    $BIOL
    Medical/Dental Instruments
    Health Care

    $BIOL
    SEC Filings

    View All

    SEC Form 8-K filed by Biolase Inc.

    8-K - BIOLASE, INC (0000811240) (Filer)

    10/8/24 4:47:14 PM ET
    $BIOL
    Medical/Dental Instruments
    Health Care

    Biolase Inc. filed SEC Form 8-K: Bankruptcy or Receivership

    8-K - BIOLASE, INC (0000811240) (Filer)

    10/1/24 4:05:10 PM ET
    $BIOL
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by Biolase Inc.

    8-K - BIOLASE, INC (0000811240) (Filer)

    9/6/24 4:05:08 PM ET
    $BIOL
    Medical/Dental Instruments
    Health Care

    $BIOL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BIOLASE Showcases Advanced YSGG Laser Solutions for Periodontal and Implant Care at GNYDM 2025

    NEW YORK, Nov. 25, 2025 /PRNewswire/ -- BIOLASE, the global leader in dental lasers, announced its participation in the 2025 Greater New York Dental Meeting (GNYDM), taking place November 28–December 3 in New York City. As part of the program, BIOLASE will host a featured lecture led by Philip Kang, DDS, focused on advancing laser solutions for periodontal and implant health. BIOLASE to Highlight YSGG Laser Innovations at GNYDM 2025 Dr. Kang will present "Advancing Laser Solutions for Periodontal and Implant Health" on Sunday, November 30 from 10:00 AM to 12:30 PM on the GNYDM

    11/25/25 9:00:00 AM ET
    $BIOL
    Medical/Dental Instruments
    Health Care

    BIOLASE Voluntarily Initiates Chapter 11 Proceedings

    LAKE FOREST, CA / ACCESSWIRE / October 1, 2024 / BIOLASE, Inc. (NASDAQ:BIOL) (the "Company"), a global leader in dental lasers, today announced that the Company and its direct domestic subsidiaries have voluntarily initiated Chapter 11 proceedings (the "Bankruptcy Petitions") in the United States Bankruptcy Court for the District of Delaware (the "Court"). BIOLASE will seek Court approval to continue operating during the proceedings and remains focused on providing its customers with its award-winning dental lasers and customer service.The Company also announced today that it is pursuing a sale process under Section 363 of the Bankruptcy Code in conjunction with the filing. To this end, BIOL

    10/1/24 4:05:00 PM ET
    $BIOL
    Medical/Dental Instruments
    Health Care

    BIOLASE Reports 2024 Second Quarter Results; Achieves 40% Gross Margin as Global Consumable Sales Strengthen

    LAKE FOREST, CA / ACCESSWIRE / August 8, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the second quarter ended June 30, 2024."We experienced another strong quarter in consumable revenue, recording our second-highest mark ever and achieving over 600 recurring subscriptions," commented John Beaver, President and Chief Executive Officer of BIOLASE. "This success translates to over $2 million in scheduled shipments over the next twelve months. Our gross margin increased to 40%, up from 33% in the first quarter of 2024, due to cost reduction efforts implemented earlier in the year. Despite ongoing revenue challenges due to highe

    8/8/24 4:05:00 PM ET
    $BIOL
    Medical/Dental Instruments
    Health Care

    $BIOL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Colliers Securities resumed coverage on BIOLASE with a new price target

    Colliers Securities resumed coverage of BIOLASE with a rating of Buy and set a new price target of $1.15

    3/8/21 4:09:02 AM ET
    $BIOL
    Medical/Dental Instruments
    Health Care

    Maxim Group reiterated coverage on BIOLASE with a new price target

    Maxim Group reiterated coverage of BIOLASE with a rating of Buy and set a new price target of $2.00 from $1.00 previously

    1/26/21 4:24:15 PM ET
    $BIOL
    Medical/Dental Instruments
    Health Care

    $BIOL
    Leadership Updates

    Live Leadership Updates

    View All

    Strateos Appoints Alexander K. Arrow as Chief Financial Officer and Expands Team

    Juliet M. Moritz appointed Vice President, Project Management Office Strateos, Inc., a pioneer in the development of remote access laboratories and lab automation software for life science research, today announced the appointment of Alexander K. Arrow, MD, CFA, as Chief Financial Officer. Dr. Arrow will join the Executive Leadership team and play a key role in leading the company's business and finance strategy focused on growth and new investments. The company has also named Juliet M. Moritz, MPH, Vice President, Project Management Office, reflecting the significant demand by large pharmaceutical companies and contract research organizations for deployment of Strateos Lodestar™ Software.

    2/8/23 8:00:00 AM ET
    $BIOL
    Medical/Dental Instruments
    Health Care

    BIOLASE NAMES DR. RUSSELL MORROW AS CHIEF DENTAL OFFICER

    Dr. Morrow brings extensive clinical, dental and DSO experience to help expand laser adoption globally LAKE FOREST, Calif., Oct. 13, 2022 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ:BIOL), a global leader in dental lasers, today announced the appointment of Russell Morrow, D.D.S. as Chief Dental Officer ("CDO"), effective November 1, 2022. Dr. Samuel Low, who has served as Chief Dental Officer since 2016, will be taking on a new role as Vice President, Clinical Strategic Alliances, where he will focus on building partnerships and growth with Dental Service Organizations (DSOs), universities and government institutions.

    10/13/22 6:30:00 AM ET
    $BIOL
    Medical/Dental Instruments
    Health Care

    BIOLASE Expands Core Capabilities As It Appoints Three New Board Members With Significant Dental Experience

    FOOTHILL RANCH, Calif., Aug. 16, 2021 /PRNewswire/ -- Demonstrating a deep commitment to expanding the core capabilities and diversity of its Board of Directors, BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced it has appointed three new board members to its Board of Directors (the "Board"), effective immediately. Drs. Kathleen T. O'Loughlin, Carol Gomez Summerhays, and Martha Somerman join a Board that has been instrumental in establishing and implementing the Company's business plan, which has demonstrated significant growth over the past several quarters.

    8/16/21 6:30:00 AM ET
    $BIOL
    Medical/Dental Instruments
    Health Care

    $BIOL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Biolase Inc.

    SC 13G - BIOLASE, INC (0000811240) (Subject)

    2/23/24 4:05:29 PM ET
    $BIOL
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Biolase Inc.

    SC 13G - BIOLASE, INC (0000811240) (Subject)

    2/21/24 4:39:54 PM ET
    $BIOL
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Biolase Inc.

    SC 13G - BIOLASE, INC (0000811240) (Subject)

    2/14/24 4:06:57 PM ET
    $BIOL
    Medical/Dental Instruments
    Health Care

    $BIOL
    Financials

    Live finance-specific insights

    View All

    BIOLASE Reports 2024 Second Quarter Results; Achieves 40% Gross Margin as Global Consumable Sales Strengthen

    LAKE FOREST, CA / ACCESSWIRE / August 8, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the second quarter ended June 30, 2024."We experienced another strong quarter in consumable revenue, recording our second-highest mark ever and achieving over 600 recurring subscriptions," commented John Beaver, President and Chief Executive Officer of BIOLASE. "This success translates to over $2 million in scheduled shipments over the next twelve months. Our gross margin increased to 40%, up from 33% in the first quarter of 2024, due to cost reduction efforts implemented earlier in the year. Despite ongoing revenue challenges due to highe

    8/8/24 4:05:00 PM ET
    $BIOL
    Medical/Dental Instruments
    Health Care

    SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

    DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st

    7/17/24 4:15:00 PM ET
    $BIOL
    $BTCY
    $DERM
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Biolase Reports 2024 First Quarter Results; Reiterates Full-Year 2024 Guidance For Revenue Growth and Profitability

    Increased Adoption of Dental Lasers and Improved Cost Structure Position Company for Sustained Long Term Growth and SuccessLAKE FOREST, CA / ACCESSWIRE / May 13, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the first quarter ended March 31, 2024.First Quarter Financial HighlightsGenerated increased adoption of its industry-leading laser, with approximately 67% of U.S. Waterlase sales coming from new customers and approximately 42% from dental specialistsThird strongest consumable sales quarter in company history, with consumable sales increasing 14% year over year, largely driven by over 600 subscriptionsGross margin was re

    5/13/24 4:05:00 PM ET
    $BIOL
    Medical/Dental Instruments
    Health Care